Management Team

  • Richard J. MacKay

    With over 50 years of experience in the pharmaceutical industry, Richard J. MacKay is now recognized as an icon within the field of dermatology. In 1976, he launched the Canadian division of Stiefel Laboratories Inc. and subsequently launched many subsidiaries for Stiefel in his role as Vice-Chairman.

    Dick joined Valeo Pharma as Chairman following the sale of Stiefel to GSK. He brings a wealth of knowledge and an unparalleled level of expertise in pharmaceutical management.

  • Steve Saviuk
    President and CEO

    Steve has an extensive background in finance and venture capital investing including a number of successful health science companies. He co-founded Valeo Pharma in 2003 and has served as its President and CEO since its inception and has overseen its transformation from its early years as an in-licensor of established brands to a fast growing full service Canadian pharmaceutical company.

  • Marc Léger
    Executive Vice-President, Commercial Operations

    Marc has extensive experience in the Pharmaceutical industry in both Canada and the U.S. Included in this background is General Manager experience, as well as several senior VP positions in Sales and Marketing, in both the prescription and OTC businesses. Marc has built a reputation for success in Business Management through strong leadership and a solid track record for launching #1 in class brands.

  • Kristof Biniecki Ph.D. in Pharmacy
    Vice-President Scientific Affairs

    With over 25 years of experience with a multinational in the areas of Quality Assurance, Quality Control and Regulatory Affairs, he successfully launched several Rx and OTC products. These functions also entailed global custom manufacturing involving international audits and on-site project development. As a result, his expertise in product development from the early stages of drug submission preparation up to its commercialization is extremely beneficial to the Valeo Pharma team.

  • Helen Saviuk, C.A.
    Vice-President Finance & Chief Financial Officer

    Helen has held various positions in financial accounting throughout her career. She has been active in Valeo since its inception in 2003 and was involved in setting the base structure for various departments of the company, specifically concentrating on all financial operations as well as supply chain management.

  • Dominique Jeandupeux
    Director, Regulatory Affairs

    Dominique Jeandupeux has been working in the field of Canadian Regulatory Affairs for over 25 years, most of it within international pharmaceutical companies. During this time, he has gathered regulatory expertise with several types of products which includes sterile drugs, semi-solid dosage forms, NHPs and cosmetics. Dominique is responsible for all of Valeo's regulatory filings with Health Canada. Other responsibilities include managing the entire aspect of Pharmacovigilance and protecting intellectual property.

    Dominique has a master degree in neurophysiology from McGill University.

  • David Newell
    Director, Marketing

    David Newell B. Comm, CCPE, has served as Valeo Pharma Inc.'s Marketing Director since 2011. David brings a broad base of pharmaceutical experience from a brand and generic market perspective. He has held roles of increasing responsibility in sales and marketing with GSK and Merck. David understands the evolving brand and generic working environments and helps to define our product strategies and oversees their successful implementation.

  • Jeff Skinner
    Vice President, Business Development

    Jeff has fifteen years experience with healthcare organizations, specifically in Business Development, and brings a long deal sheet having completed a wide range of deal types in Specialty Pharma, Biotech and Generic licensing agreements.